ATE273708T1 - Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt - Google Patents

Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt

Info

Publication number
ATE273708T1
ATE273708T1 AT95909122T AT95909122T ATE273708T1 AT E273708 T1 ATE273708 T1 AT E273708T1 AT 95909122 T AT95909122 T AT 95909122T AT 95909122 T AT95909122 T AT 95909122T AT E273708 T1 ATE273708 T1 AT E273708T1
Authority
AT
Austria
Prior art keywords
txa2
prophylaxis
treatment
pct
mediated diseases
Prior art date
Application number
AT95909122T
Other languages
English (en)
Inventor
Ruriko Ikegawa
Teruaki Imada
Norifumi Nakamura
Keizo Tanikawa
Nobutomo Tsuruzoe
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Application granted granted Critical
Publication of ATE273708T1 publication Critical patent/ATE273708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
AT95909122T 1994-02-22 1995-02-20 Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt ATE273708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2455694 1994-02-22
PCT/JP1995/000244 WO1995022329A1 (en) 1994-02-22 1995-02-20 Agent for prophylaxis and treatment of thromboxane a2-mediated diseases

Publications (1)

Publication Number Publication Date
ATE273708T1 true ATE273708T1 (de) 2004-09-15

Family

ID=12141437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909122T ATE273708T1 (de) 1994-02-22 1995-02-20 Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt

Country Status (16)

Country Link
US (1) US5798357A (de)
EP (1) EP0744950B1 (de)
JP (1) JP3858279B2 (de)
KR (1) KR100345187B1 (de)
CN (1) CN1084620C (de)
AT (1) ATE273708T1 (de)
AU (1) AU1718395A (de)
CA (1) CA2183234C (de)
DE (1) DE69533392T2 (de)
DK (1) DK0744950T3 (de)
ES (1) ES2222464T3 (de)
FI (1) FI116882B (de)
IL (1) IL112695A (de)
NO (1) NO311490B1 (de)
WO (1) WO1995022329A1 (de)
ZA (1) ZA951470B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
DE69832089T2 (de) * 1997-08-28 2006-07-20 Nissan Chemical Industries, Ltd. Mittel zur förderung und verstärkung der neovaskularisierung
US6143113A (en) 1998-03-02 2000-11-07 Le Groupe Recherche I.D. Inc. Repulpable corrugated boxboard
RU2229297C2 (ru) 1998-09-01 2004-05-27 Ниссан Кемикал Индастриз, Лтд. Терапевтический агент для лечения стеноза позвоночного канала
CA2353956C (en) * 1998-12-07 2008-10-28 Nissan Chemical Industries, Ltd. Remedial agent for erectile dysfunction
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
EP2244710A4 (de) * 2008-01-29 2011-06-01 Indigo Pharmaceuticals Verfahren zur verabreichung eines pde3-hemmers mittels titrierung zur behandlung von peripherer artieller verschlusskrankheit
CN113546049B (zh) * 2021-04-30 2023-03-17 贵州汉方药业有限公司 一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599336A (en) * 1983-08-08 1986-07-08 Hoffmann-La Roche Inc. Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
EP0142057A3 (de) * 1983-11-04 1988-03-30 F. Hoffmann-La Roche Ag Thiazolochinazolin-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zubereitungen
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
ES2149761T3 (es) * 1990-04-25 2000-11-16 Nissan Chemical Ind Ltd Derivado de piridazinona.

Also Published As

Publication number Publication date
JP3858279B2 (ja) 2006-12-13
WO1995022329A1 (en) 1995-08-24
NO963463L (no) 1996-08-20
AU1718395A (en) 1995-09-04
CA2183234A1 (en) 1995-08-24
NO311490B1 (no) 2001-12-03
IL112695A0 (en) 1995-05-26
US5798357A (en) 1998-08-25
KR970701048A (ko) 1997-03-17
FI963264A (fi) 1996-08-21
EP0744950B1 (de) 2004-08-18
DE69533392D1 (de) 2004-09-23
FI116882B (fi) 2006-03-31
CN1084620C (zh) 2002-05-15
IL112695A (en) 1999-04-11
FI963264A0 (fi) 1996-08-21
CN1141590A (zh) 1997-01-29
ZA951470B (en) 1995-12-07
KR100345187B1 (ko) 2002-12-05
DK0744950T3 (da) 2004-10-25
JPH07285869A (ja) 1995-10-31
CA2183234C (en) 2004-05-04
EP0744950A1 (de) 1996-12-04
DE69533392T2 (de) 2005-09-01
ES2222464T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
ZA953469B (en) New compound
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
IL112841A0 (en) Sulfonamide aspartyl protease inhibitors methods for the preparation thereof and pharmaceutical compositions containing the same
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
IL107505A (en) N-substituted arylalkynyl- and N-substituted heteroaryl alkynyl N-hydroxyurea inhibitors of leukotriene biosynthesis and compositions comprising same
IN2005KO00312A (de)
ATE273708T1 (de) Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt
ATE245447T1 (de) Inhibitor von gehirnödemen
DE60318874D1 (en) Pyrazolderivate
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
NO975726D0 (no) N-Hydroksyurea-derivater som anti-inflammatoriske midler
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.
AU2003263455A1 (en) Pyrazole amides for treating hiv infections
DE60321700D1 (de) Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten
UY25369A1 (es) Procedimiento para preparar inhibidores de proteasa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0744950

Country of ref document: EP